The U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) number ANDA088292 for imipramine hydrochloride tablets.
The product, marketed under the brand name Imipramine Hydrochloride, is manufactured by Strides Pharma Science Limited. It is an oral prescription tablet available in a 10 mg strength.
The FDA listing includes several National Drug Code (NDC) identifiers—product NDCs 64380-169, 64380-170, and 64380-171—and corresponding package codes such as 64380-169-01, 64380-169-02, 64380-170-01, 64380-170-02, 64380-171-01, and 64380-171-02. The product type is classified as a human prescription drug.
Submission records show multiple manufacturing (CMC) submissions dating from 1983 to 1997 and labeling submissions up to 2005, all with an approved (AP) status.
Actualizaciones regulatorias30 ago 2026•1 min de lectura
FDA Approves Imipramine Hydrochloride (ANDA088292)
FDA grants approval for ANDA088292, an oral imipramine hydrochloride tablet by Strides Pharma Science Limited, with details on dosage, NDC codes, and submission history.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración